Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 898123 | ISIN: US9418481035 | Ticker-Symbol: WAZ
Tradegate
16.01.25
16:57 Uhr
386,60 Euro
-6,40
-1,63 %
Branche
Sonstige Technologie
Aktienmarkt
S&P 500
1-Jahres-Chart
WATERS CORPORATION Chart 1 Jahr
5-Tage-Chart
WATERS CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
387,30397,0018.01.
391,90393,9017.01.
PR Newswire
419 Leser
Artikel bewerten:
(2)

Waters Corporation: Waters ACQUITY QDa II Mass Detector Delivers Wider Range of Chemical Analysis within Cost-Effective, Lower Energy Instrument

Finanznachrichten News

News Summary:

  • ACQUITY QDa II Mass Detector enhances confidence in routine compound identification using the specificity of mass analysis to boost efficiency, robustness, and productivity in LC-UV separations, while leveraging the Empower Chromatography Data System for complete traceability.
  • Provides a 20% enhancement in mass rangei for broader analytical support of large molecule and new drug modalities in the development pipeline.
  • Up to 70% lower energy consumption and heat output compared with competing productsii earns recognition from My Green Lab with an Accountability, Consistency, and Transparency (ACT) Label.

MILFORD, Mass., May 8, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the release of the ACQUITY QDa II Mass Detector, the evolution of its highly successful, compact, and streamlined mass detection instrument that delivers high-quality, mass spectral data to chromatographic separations. This new and improved mass detector allows scientists to analyze a wider range of chemical entities with a robust, cost-effective, low energy consumption solution. It enhances and complements Waters best-in-class ACQUITY Premier Liquid Chromatography (LC) separations portfolio to enable flexible analysis of both small and large molecules across pharmaceutical, food, chemical, and materials applications.

"Since we launched the first-generation ACQUITY QDa Mass Detector on Empower Chromatography Data System in 2013, it has become an essential tool for chromatographers looking to accelerate the development of higher quality methods for product development and impurity analysis," said James Hallam, Vice President for Research, Development, and Advanced Testing, Waters Corporation. "As we designed the ACQUITY QDa II Mass Detector, we extended the capabilities of the new system to address the expansion of new molecular entities, such as monoclonal antibodies and glucagon-like peptide 1 (GLP-1) agonist."

The ACQUITY QDa II Mass Detector is designed to seamlessly integrate into existing laboratory workflows with the usability and format of a LC detector. It delivers a 20% enhancement in mass range in a simple, small footprint LC-MS instrument designed to seamlessly integrate into highly regulated laboratory settings, ensuring compliance with ease.

"We simply cannot afford any time lag in results as even a short delay in getting the right analysis can mean a finished product might not be able to be released for the needs of a patient population," said Mariusz Kurowski, Analytical and API Expert, Polpharma, Poland's largest pharmaceutical manufacturer. "Mass spec is a sophisticated technique, but we have seen the incredible ease-of-use with the ACQUITY QDa Mass Detector; we see this instrument as the future for us."

To enable scientists to deploy mass detection closer to the point of need, the ACQUITY QDa II Mass Detector also delivers improvements in repeatability and offers up to a 70% reduction in energy consumption and heat output compared to similar instruments. These efficiency and energy consumption improvements have earned the ACQUITY QDa II Mass Detector the ACT Label from the independent, nonprofit My Green Lab. The recognition is given to laboratory equipment that meets or exceeds the sustainability requirements of environmentally conscious laboratories.

The ACQUITY QDa II Mass Detector is designed for compliance-ready deployment on Waters Empower Chromatography Data System (CDS) Software. It enables streamlined integration of mass measurements into chromatographic methods, making it accessible to analytical scientists who do not have expertise in mass spectrometry. It is designed to complement and work with the best-in-class Waters ACQUITY Premier Liquid Chromatography (LC) portfolio and is now available to order online globally.

Additional Resources

  • Learn more about the new Waters QDa II Mass Detector
  • See list of Waters products that earned ACT Labels from My Green Lab
  • Follow and connect with Waters via LinkedIn, Twitter, and Facebook

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,700 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Waters, ACQUITY, QDa, and Empower are trademarks of Waters Technologies Corporation.

Contact:

Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
janice_foley@waters.com
+1.617.823.5555

i QDa II offers an extended mass range up to 1500m/z compared to 1250m/z from previous QDa mass detector, providing a 20% increase to cover more compounds (according to Waters new product capabilities document).

ii Comparison based on publicly available data of power consumption and BTU output of QDa II vs. similar competitor products.

Waters Corporation

Logo - https://mma.prnewswire.com/media/2071755/Waters_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/waters-acquity-qda-ii-mass-detector-delivers-wider-range-of-chemical-analysis-within-cost-effective-lower-energy-instrument-302139761.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.